Epitel Secures $26 Million Series B to Expand Remote Wireless EEG Monitoring
Funding will drive commercial expansion of the first fully wireless FDA-cleared EEG system, making AI-driven remote brain monitoring more widely available to patients and providers.
SALT LAKE CITY–(BUSINESS WIRE)–Epitel, Inc., a leader in AI-driven wireless brain health technologies, announced today the closing of a $26 million Series B financing co-led by Catalyst Health Ventures and Genoa Ventures, with participation from new and existing investors. The funding will support the continued market expansion of the company’s REMI® Remote EEG Monitoring System, allowing extended duration wireless EEG monitoring integrated with AI-driven event detection to improve access to neurological care.
